AbbVie showcases breakthrough ADC hard-to-treat cancers data at ESMO 2025
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers